Abstract: A method is provided for producing an effective adjuvant response or stimulating the immune response of a warm blooded animal which comprises administering to said warm blooded animal an effective amount of a composition comprising refined detoxified endotoxin in combination with a pharmaceutically acceptable carrier.

Abstract: DNA constructs consisting essentially of the promoter, gag, pol, and env sequences of a helper virus useful for making retrovirus packaging cell lines that do not yield helper virus and do not transfer the packaging function. Such DNA molecules are constructed by deleting from the genome of a replication-competent retrovirus all cis-acting elements except for the tRNA binding site. Specifically, deletion is made of the packaging signal, the site for initiation of second strand DNA synthesis, the site required for translation of reverse transcriptase during first strand DNA synthesis, and the provirus integration signal. DNA construct pPAM3 (ATCC No. 40234) is a representative embodiment. A cell line containing such an altered viral genome does not transmit this virus or transfer the packaging signal, but will transmit high titers of other viral RNAs containing the proper cis-acting elements, including retroviral vectors designed to carry foreign genes. Cell line PA317 (ATCC No.

Abstract: A cycloheximide resistant gene of the present invention can be produced by cultivating yeast belonging to Candida genus and by cleaving a cycloheximide resistant gene from the yeast using restriction enzymes XbaI and Sau3AI.By incorporating the cycloheximide resistant gene together with the gene for useful substance into a plasmid, the transformant producing useful substance can be readily detected.

Abstract: A vaccine derived from Bordetalla bronchiseptica effective against Bordetella pertussis infection is disclosed herein.

Abstract: Novel DNA sequences which are responsive to the presence of methanol, catabolite non-repressing carbon sources and carbon source starvation are provided. In addition, novel constructs including these DNA sequences, as well as transformed organisms therewith are provided. Processes for producing the DNA sequences and constructs of the invention are detailed. The production of polypeptide product under the control of the regulatory regions of the invention is demonstrated.

Abstract: There is disclosed a DNA transfer vector capable of replication in either a yeast cell or a bacterial cell and having inserted therein a DNA segment coding for human WA rotavirus surface antigen VP7. The transfer vector carrying the foreign DNA is used to transform yeast cells in order to produce the surface antigen VP7 which is capable of eliciting in vivo production of neutralizing antibodies with respect to human WA rotavirus. The surface antigen VP7 so elaborated and its use in a pharmaceutical vaccine composition are also disclosed.

Abstract: Vector plasmids are constructed to provide sites for insertion of a structural gene in phase with three reading frames downstream from the promoter of alkaline phosphatase gene of Escherichia coli.

Abstract: A method is provided for expressing human alpha-1-antitrypsin in yeast utilizing a wild-type strain and a hyperproduction mutant, GK100.

Abstract: Novel autonomous replication sequences which are capable of maintaining plasmids as extrachromosomal elements in host strains of the genus Pichia are provided. In addition, novel constructs including these DNA sequences, as well as transformed organisms therewith are provided. Processes for producing the DNA sequences and constructs of the invention, as well as method for isolating such sequences from any source, are provided.

Abstract: The present invention relates to a DNA fragment having a promoter activity of PHO81 gene regulating the production of phosphatase, and which is obtainable from Saccharomyces cerevisiae.; a DNA fragment bearing a structural gene downstream from the above PHO81 promoter; a transformant containing a DNA fragment bearing the above PHO81 promoter; a transformant containing a DNA fragment bearing the above PHO81 promoter and a structural gene downstream from the PHO81 promoter; and a process for obtaining a gene product which includes culturing a transformant containing a DNA fragment bearing the above PHO81 promoter and a structural gene located downstream therefrom in a suitable medium until the gene product is formed and recovering the gene product from the culture. Pharmacologically important proteinous materials may be efficiently produced with the use of the above-described novel and potent promoter obtained from yeast which is a eukaryotic microorganism.

Abstract: A fusion between DNA sequences coding for hAT and hGRF via a synthetic adaptor coding for an in vitro cleavable amino acid sequence is used to express hGRF at high levels in E. coli.

Abstract: A strain of yeast Saccharomyces cerevisiae has been developed which, when grown under defined culture conditions, will produce protein indistinguishable from wheat gluten protein. This new yeast strain was developed by introducing a specially constructed autonomously replicating extrachromosomal genetic element, gluten plasmid pAY31, into the parent yeast strain. This plasmid is a circular DNA molecule, constructed by enzymic fusion of the following elements: (1) the E.

Abstract: Glucagon or fragments or derivatives thereof are prepared by cultivation of a yeat strain transformed with a replicable expression vehicle comprising a gene encoding the expression of such products. Synthetic genes encoding glucagon or derivatives thereof have been constructed. Also provided are replicable expression vehicles comprising a replication system for providing stable maintenance in yeast and a DNA-sequence encoding glucagon or fragments or derivatives thereof and transformant yeast strains containing such expression vehicles.

Abstract: A novel species of alpha interferon is taught. The alpha interferon amino acid sequence is disclosed and a gene corresponding thereto. The alpha interferon gene is expressed in Escherichia coli.

Abstract: Novel DNA sequences which code for the production of the Pichia protein argininosuccinate lyase are provided. Novel constructs including these sequences, as well as organisms transformed therewith are provided. In addition, novel strains of Pichia defective in argninosuccinate lyase activity are also provided.

Abstract: This invention relates to antibody-metal ion complexes having a metal ion coordinately bound to a compatible chelator covalently bound to an antibody or antibody fragment. Also described are methods for intermediates in the preparation of antibody-metal ion complexes. Therapeutic and in vitro and in vivo diagnostic methods utilizing such antibody-metal ion complexes are described.

Abstract: Candida albicans has been transformed by the insertion of a plasmid comprising a fragment of DNA from Candida albicans containing the intact ADE 2 gene.

Abstract: Human Tumor necrosis factor (TNF) has been prepared using recombinant methods. A human promyelocytic leukemia cell line has been induced using an improved induction procedure, and the TNF purified to homogeneity. Methods, vectors, and cells useful in obtaining human TNF in practical amounts are disclosed. Muteins having N-terminal deletions, which muteins have superior biological activity, are also disclosed.

Abstract: Human tumor necrosis factor (TNF) has been prepared using recombinant methods. A human promyelocytic leukemia cell line has been induced using an improved induction procedure, and the TNF purified to homogeneity. Methods, vectors, and cells useful in obtaining human TNF in practical amounts are disclosed. Muteins having N-terminal deletions, which muteins have superior biological activity, are also disclosed.

Abstract: A method is described for the covalent attachment of linker groups to specific sites on antibody molecules directed against any desired target antigen (tumor, bacterial, fungal, viral, parasitic etc.). These linkers can be attached via amide or ester bonds to compounds for delivery which contain available amino or hydroxy groups (e.g., bioactive agents, cytotoxic agents, dyes, fluors, radioactive compounds, etc.). In addition the linkers can be incorporated into insoluble matrices for use in separation schemes which are based upon antibody-antigen interactions.The linkers may be designed so that they are susceptible to cleavage by any one of the serum complement enzymes. When prepared according to the methods described herein, the resulting modified antibody molecule retains the ability to bind antigen and to fix serum complement. Thus, when administered to a patient the antibody conjugate binds to its target in vivo.